| Source: |
| Type: |
| AntiTumor |
| 5269- | 3BP, | The anti-metabolite KAT/3BP has in vitro and in vivo anti-tumor activity in lymphoma models. |
| - | in-vitro, | HCC, | NA |
| 5314- | acetaz, | Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment |
| - | Review, | Var, | NA |
| 5462- | AF, | Repurposing Auranofin for Oncology and Beyond: A Brief Overview of Clinical Trials as Mono- and Combination Therapy |
| - | Review, | Var, | NA |
| 5471- | AF, | Anti-Tumoral Treatment with Thioredoxin Reductase 1 Inhibitor Auranofin Fosters Regulatory T Cell and B16F10 Expansion in Mice |
| - | vitro+vivo, | Melanoma, | B16-F10 |
| 1295- | AG, | Cisplatin, | Chemosensitizing Effect of Astragalus Polysaccharides on Nasopharyngeal Carcinoma Cells by Inducing Apoptosis and Modulating Expression of Bax/Bcl-2 Ratio and Caspases |
| - | in-vivo, | Laryn, | NA |
| 5444- | AG, | A Systematic Review of Phytochemistry, Pharmacology and Pharmacokinetics on Astragali Radix: Implications for Astragali Radix as a Personalized Medicine |
| - | Review, | Var, | NA |
| 5431- | AG, | Advances in research on the anti-tumor mechanism of Astragalus polysaccharides |
| - | Review, | Var, | NA |
| 4394- | AgNPs, | Silver nanoparticles provoke apoptosis of Dalton's ascites lymphoma in vivo by mitochondria dependent and independent pathways |
| - | in-vivo, | lymphoma, | NA |
| 4364- | AgNPs, | Selective cytotoxicity of green synthesized silver nanoparticles against the MCF-7 tumor cell line and their enhanced antioxidant and antimicrobial properties |
| - | in-vitro, | BC, | MCF-7 |
| 4378- | AgNPs, | Exploring silver nanoparticles for cancer therapy and diagnosis |
| - | Review, | Var, | NA |
| 4383- | AgNPs, | Exploring the Potentials of Silver Nanoparticles in Overcoming Cisplatin Resistance in Lung Adenocarcinoma: Insights from Proteomic and Xenograft Mice Studies |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | Lung, | A549 |
| 4546- | AgNPs, | Chapter 2 - Silver nanoparticles in cancer therapy |
| - | Study, | Var, | NA |
| 5352- | AL, | Anticancer potential of allicin: A review |
| - | Review, | Var, | NA |
| 2657- | AL, | Allicin pharmacology: Common molecular mechanisms against neuroinflammation and cardiovascular diseases |
| - | Review, | CardioV, | NA | - | Review, | AD, | NA |
| 2593- | Api, | Apigenin promotes apoptosis of 4T1 cells through PI3K/AKT/Nrf2 pathway and improves tumor immune microenvironment in vivo |
| - | in-vivo, | BC, | 4T1 |
| 5133- | ART/DHA, | Dihydroartemisinin Exerts Anti-Tumor Activity by Inducing Mitochondrion and Endoplasmic Reticulum Apoptosis and Autophagic Cell Death in Human Glioblastoma Cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 2571- | ART/DHA, | Cancer combination therapies with artemisinin-type drugs |
| - | Review, | Var, | NA |
| 5169- | Ash, | The Tumor Inhibitor and Antiangiogenic Agent Withaferin A Targets the Intermediate Filament Protein Vimentin |
| - | in-vitro, | BC, | MCF-7 |
| 5175- | Ash, | Withaferin A Induces Proteasome Inhibition, Endoplasmic Reticulum Stress, the Heat Shock Response and Acquisition of Thermotolerance |
| - | in-vitro, | Cerv, | CCL-102 |
| 4678- | Ash, | Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer |
| - | vitro+vivo, | NSCLC, | H1975 |
| 4819- | ASTX, | Astaxanthin Induces Apoptosis in MCF-7 Cells through a p53-Dependent Pathway |
| - | in-vitro, | BC, | MCF-7 |
| 4818- | ASTX, | MEL, | Effect of astaxanthin and melatonin on cell viability and DNA damage in human breast cancer cell lines |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | T47D | - | in-vitro, | Nor, | MCF10 |
| 4804- | ASTX, | Astaxanthin in cancer therapy and prevention (Review) |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4813- | ASTX, | Astaxanthin Prevents Oxidative Damage and Cell Apoptosis Under Oxidative Stress Involving the Restoration of Mitochondrial Function |
| - | in-vitro, | AD, | NA |
| 5424- | ASTX, | Astaxanthin exerts an adjunctive anti-cancer effect through the modulation of gut microbiota and mucosal immunity |
| - | in-vivo, | Nor, | NA |
| 5448- | ATV, | Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology |
| - | Review, | Var, | NA |
| 5364- | AV, | A New Biomaterial Derived from Aloe vera—Acemannan from Basic Studies to Clinical Application |
| - | Review, | Var, | NA |
| 5365- | AV, | Aloe Vera Polysaccharides as Therapeutic Agents: Benefits Versus Side Effects in Biomedical Applications |
| - | Review, | Nor, | NA | - | Review, | IBD, | NA | - | Review, | Diabetic, | NA |
| 5577- | B-Gluc, | Lentinan progress in inflammatory diseases and tumor diseases |
| - | Review, | Var, | NA | - | Review, | IBD, | NA |
| 5580- | B-Gluc, | Lentinan, a Shiitake Mushroom β-Glucan, Downregulates the Enhanced PD-L1 Expression Induced by Platinum Compounds in Gastric Cancer Cells |
| - | in-vitro, | GC, | MKN45 |
| 876- | B-Gluc, | Clinical and Physiological Perspectives of β-Glucans: The Past, Present, and Future |
| - | Review, | NA, | NA |
| 5501- | Ba, | Therapeutic effects and mechanisms of action of Baicalein on stomach cancer: a comprehensive systematic literature review |
| - | Review, | GC, | NA |
| 5251- | Ba, | The Fascinating Effects of Baicalein on Cancer: A Review |
| - | Review, | Var, | NA |
| 2022- | BBR, | GoldNP, | Rad, | Berberine-loaded Janus gold mesoporous silica nanocarriers for chemo/radio/photothermal therapy of liver cancer and radiation-induced injury inhibition |
| - | in-vitro, | Liver, | SMMC-7721 cell | - | in-vitro, | Nor, | HL7702 |
| 2674- | BBR, | Berberine: A novel therapeutic strategy for cancer |
| - | Review, | Var, | NA | - | Review, | IBD, | NA |
| 5584- | BetA, | Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors |
| - | in-vitro, | GBM, | A172 | - | in-vitro, | GBM, | U118MG | - | in-vitro, | GBM, | U251 |
| 2724- | BetA, | Down-regulation of NOX4 by betulinic acid protects against cerebral ischemia-reperfusion in mice |
| - | in-vivo, | Nor, | NA | - | in-vivo, | Stroke, | NA |
| 2760- | BetA, | A Review on Preparation of Betulinic Acid and Its Biological Activities |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA |
| 5718- | BF, | Bufalin inhibits CYP3A4 activity in vitro and in vivo |
| - | in-vivo, | Nor, | NA |
| 5628- | Bif, | immuno, | Bifidobacterium modulation of tumor immunotherapy and its mechanism |
| - | Review, | Var, | NA |
| 5629- | Bif, | ProBio, | Gut microbiota shapes cancer immunotherapy responses |
| - | Review, | Var, | NA |
| 5686- | BJ, | BRU, | A review of Brucea javanica: metabolites, pharmacology and clinical application |
| - | Review, | Var, | NA |
| 5690- | BJ, | BRU, | Brusatol: A potential sensitizing agent for cancer therapy from Brucea javanica |
| - | Review, | Var, | NA |
| 2024- | Bos, | Antiproliferative and cell cycle arrest potentials of 3-O-acetyl-11-keto-β-boswellic acid against MCF-7 cells in vitro |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 5702- | BRU, | BJ, | Brusatol inhibits metastasis of triple-negative breast cancer through metabolic reprogramming |
| - | in-vitro, | BC, | NA |
| 2047- | Buty, | Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells |
| - | in-vitro, | CRC, | T24/HTB-9 | - | in-vitro, | Nor, | SV-HUC-1 | - | in-vitro, | Bladder, | 5637 | - | in-vivo, | NA, | NA |
| 1205- | Caff, | immuno, | Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody |
| - | in-vivo, | Melanoma, | B16-F10 |
| 2012- | CAP, | Capsaicin induces cytotoxicity in human osteosarcoma MG63 cells through TRPV1-dependent and -independent pathways |
| - | NA, | OS, | MG63 |
| 2017- | CAP, | Spice Up Your Kidney: A Review on the Effects of Capsaicin in Renal Physiology and Disease |
| - | Review, | Var, | NA |
| 2020- | CAP, | Capsaicinoids and Their Effects on Cancer: The “Double-Edged Sword” Postulate from the Molecular Scale |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:913 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid